SBRT Clinical Trial
Official title:
A Phase II Study of SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics. The investigators aim to evaluate the pathological complete response rate and safety of the combined treatment of SBRT with chemoimmunotherapy in locally advanced cancers of oral cavity and oropharynx.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04476797 -
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04587817 -
Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors
|
||
| Recruiting |
NCT04067570 -
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer
|
N/A | |
| Recruiting |
NCT02976402 -
Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy
|
Phase 1 | |
| Not yet recruiting |
NCT02940990 -
SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
|
Phase 2 | |
| Terminated |
NCT04698915 -
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04942275 -
Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04547452 -
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
|
Phase 2 | |
| Completed |
NCT03891472 -
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05344235 -
Observational Study on Extreme Hypofractionation for Localized Prostate Cancer
|